Literature DB >> 22458737

Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma.

P Jayaraj1, S Sen, A Sharma, K Chosdol, S Kashyap, A Rai, N Pushker, M S Bajaj, S Ghose.   

Abstract

BACKGROUND: E-cadherin and β-catenin are crucial components of the cell-cell adhesion complex. Their loss has often been associated with tumour metastasis and poor clinical outcome. Both loss of E-cadherin at the cell membrane and a stabilizing mutation in CTNNB1 (β-catenin gene) have been associated with ovarian, colorectal, hepatocellular and nonmelanoma skin cancer, such as squamous and basal cell carcinomas. Absence of E-cadherin may be caused by promoter hypermethylation of the E-cadherin gene (CDH1).
OBJECTIVES: To determine the role of E-cadherin promoter hypermethylation and CTNNB1 gene mutation in the aggressive behaviour of sebaceous gland carcinoma of the eyelid.
METHODS: Thirty-six cases of sebaceous gland carcinoma were subjected to E-cadherin methylation-specific polymerase chain reaction and mutational analysis for the CTNNB1 gene. E-cadherin and β-catenin staining was evaluated by immunohistochemistry. Results were correlated with the clinicopathological features of sebaceous gland carcinoma.
RESULTS: nMethylation of the E-cadherin promoter region was detected in 72% of eyelid sebaceous gland carcinoma cases and loss of E-cadherin immunostaining in 83%. E-cadherin promoter hypermethylation showed a significant association with the loss of membranous E-cadherin (P = 0·038) and it was of borderline significance with reduced disease-free survival (P = 0·05). It was also found to be associated with advanced age (73%), tumour size ≥ 2 cm (77%), orbital invasion (83%), lymph node metastasis (60%), tumour recurrence (60%) and poor histological differentiation (90%). DNA sequencing revealed no stabilizing β-catenin gene mutation in sebaceous gland carcinoma. Loss of membranous β-catenin was observed in 61% cases, which associated significantly with both E-cadherin promoter methylation (P = 0·0262) and loss of E-cadherin membranous localization (P=0·0015).
CONCLUSION: Epigenetic inactivation of the E-cadherin gene causes loss of membrane-bound E-cadherin and could contribute to the reduced disease-free survival in eyelid sebaceous gland carcinoma. Mutations in the β-catenin gene do not seem to be involved in the pathogenesis of eyelid sebaceous gland carcinoma.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22458737     DOI: 10.1111/j.1365-2133.2012.10968.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

1.  Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues.

Authors:  Jian Wu; Jin-Rong Zhang; Jie Qin
Journal:  Int J Clin Exp Med       Date:  2014-07-15

2.  Periocular sebaceous gland carcinoma: A comprehensive review.

Authors:  Kaustubh Mulay; Ekta Aggarwal; Valerie A White
Journal:  Saudi J Ophthalmol       Date:  2013-07

3.  Quantitative gene analysis of methylation and expression (Q-GAME) in fresh or fixed cells and tissues.

Authors:  Jianqiang Wu; Katrin A Salva; Nathalie Stutz; B Jack Longley; Vladimir S Spiegelman; Gary S Wood
Journal:  Exp Dermatol       Date:  2014-05       Impact factor: 3.960

4.  Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy.

Authors:  Katja Storch; Nils Cordes
Journal:  Chemother Res Pract       Date:  2012-06-18

Review 5.  Orchestrating epigenetic roles targeting ocular tumors.

Authors:  Xuyang Wen; Linna Lu; Zhang He; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2016-02-29       Impact factor: 4.147

6.  Immunohistochemical expression of X-linked inhibitor of apoptosis in eyelid sebaceous gland carcinoma predicts a worse prognosis.

Authors:  Perumal Jayaraj; Seema Sen; P S Dhanaraj; Romika Jhajhria; Shalu Singh; Vijay Kumar Singh
Journal:  Indian J Ophthalmol       Date:  2017-11       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.